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Abstract
Botulinum neurotoxin (BoNT) is a major therapeutic agent licensed in neurological indi-
cations such as dystonia and spasticity. In recent years, its use has steadily increased 
in other neurological areas and new therapeutic areas and also in the aesthetic setting. 
Paradoxically, BoNT is also the causative agent of the disease botulism and a potential 
bioterrorism toxin. The BoNT family of toxins comprised more than 40 individual mem-
bers, classified into 7 serotypes and are produced by Gram-positive obligate anaerobic 
bacteria. BoNTs are enzymatic multi-modular proteins with a complex multistep mecha-
nism of action. Their target site is at peripheral neurons, particularly the neuromuscular 
junction, at which they inhibit acetylcholine neurotransmission. Despite intense activ-
ity in the BoNT field, today there are still gaps in knowledge both in clinical practice 
and in basic research. The discovery of the structure-function of BoNT and its domains 
has allowed rational design of new features using molecular engineering. The diversity 
of BoNT molecules, both natural and engineered, is an invaluable pool from which to 
design future new therapeutics with unique pharmacological properties for current and 
novel indications.
Keywords: botulinum neurotoxin, therapeutic agent, botulism, recombinant protein, 
targeted secretion inhibitor
1. Introduction
There are currently four botulinum neurotoxin (BoNT) clinical products available in the 
Western hemisphere: abobotulinumtoxinA (Dysport®, Ipsen, Paris, France), incobotulinum-
toxinA (Xeomin®, Merz Pharmaceuticals GmbH, Frankfurt, Germany), onabotulinum-
toxinA (Botox®, Allergan, Irvine, CA, USA) and rimabotulinumtoxinB (Myobloc®, Solstice 
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Neurosciences, Louisville, KY, USA) [1]. Several other products are available for use in other 
countries, in particular in the Asian markets, and new formulations and products are under-
development [2]. By 2022, it is expected that the market size for botulinum products will reach 
$6.6 billion, driven by the expansion of their therapeutic uses and also the appetite for non-
invasive aesthetic applications [3].
Around 200 years ago (between 1817 and 1822), a German medical officer, Justinus Kerner, 
published a series of papers to provide the first accurate and complete description of the 
symptoms of food-borne botulism, which led to the discovery of BoNT as the causative agent 
and the prediction by Kerner of its potential clinical utility [4]. This fascinating class of pro-
teins present a modular molecular architecture with distinct binding, translocation and enzy-
matic domains. The different structural and functional domains can be regarded as ‘building 
blocks’ and have facilitated a number of engineering approaches aimed, amongst other pur-
poses, at extending the therapeutic applications of BoNTs to other cell types beyond their 
natural target of the neuromuscular junction [5].
The aim of this chapter is to (1) provide an overview of the current clinical uses and a histori-
cal perspective of botulinum neurotoxin discovery, the disease it causes and the threats and 
opportunities that it poses and (2) present the current understanding of the structure-function 
of the toxin and its application in the development of new therapeutics.
2. Clinical uses
BoNT products are neuromuscular blocking agents which exert their effect through inhibi-
tion of acetylcholine release. BoNTs are amongst the most tissue-selective drugs known 
in clinical pharmacology and are characterised by high potency, high specificity and long 
duration of action of around 3–6 months following a single injection [6]. These character-
istics have made BoNTs highly successful and effective therapeutic agents for the man-
agement of several chronic and debilitating diseases of neuronal hyperactivity. Although 
initially thought to inhibit acetylcholine release only at the neuromuscular junction, BoNTs 
are recognised to also inhibit release of neurotransmitters from autonomic nerve terminals, 
for example, in glands (e.g. in hyperhidrosis), and nociceptive neurons in pain states [6, 7].
Currently, there are four formulations of BoNTs approved by the US Food and Drug 
Administration (FDA) for several clinical applications (see Table 1). Cervical dystonia, also 
known as spasmodic torticollis (disorder characterised by involuntary contractions of neck 
and upper shoulder muscles resulting in abnormal postures and/or movement of the neck, 
shoulder and head and that may be associated with neck pain), is the only condition for 
which all four formulations are approved. Other neurological conditions include spasticity 
(disorder characterised by tight or stiff muscles and an inability to control those muscles), 
with approved formulations both for adult and paediatric populations, migraine and blepha-
rospasm (dystonia that can cause disabling eye closure). Other non-neurological therapeutic 
FDA-approved uses are strabismus (eye misalignment), overactive bladder, urinary inconti-
nence and hyperhidrosis (excessive sweating).
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FDA-approved 
indication
Treatment population AbobotulinumtoxinA
(Dysport®)
IncobotulinumtoxinA
(Xeomin®)
OnabotulinumtoxinA
(Botox®)
RimabotulinumtoxinB
(Myobloc®)
Cervical dystonia Adult Approved Approved Approved Approved
Upper limb spasticity Adult Approved Approved Approved na
Lower limb spasticity Adult na na Approved na
Lower limb spasticity Children ≥ 2 years of 
age
Approved na na na
Migraine Adult na na Approved na
Blepharospasm ≥12 years of age na Approved Approved na
Strabismus ≥ 12 years of age na na Approved na
Glabellar lines Adult Approved Approved Approved na
Overactive bladder Adult na na Approved na
Urinary incontinence Adult na na Approved na
Hyperhidrosis Adult na na Approved na
na = indication not FDA-approved.
Table 1. Food and Drug Administration (FDA)-approved indications for the use of marketed botulinum neurotoxins products [1].
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Historically, BoNT products have been considered as a single pharmacological class [8]. 
However, the existing BoNT products vary in the identity and amount of toxin present, their 
formulations, the manufacturing processes and the potency methods used to determine the 
strength of the products [9, 10]. As a result, the different products are not considered to be 
interchangeable, and their respective clinical efficacy and safety are unique to each specific 
product [11].
In 2016, the American Academy of Neurology (AAN) published updated guidelines for the 
clinical use of BoNT [12]. The 2016 AAN recommendations for BoNT use, based on evidence 
from clinical trials, do not fully match the FDA-approved indications or AAN’s previous 
guidelines from 2008, which is a reflection of the expanding uses of BoNTs [8]. Multiple clini-
cal trials are being conducted to investigate the efficacy and safety of BoNTs for various clini-
cal conditions and, in addition, pilot studies are being conducted to test the efficacy of BoNTs 
for new indications [9, 13, 14]. A summary of not approved new indications for which botuli-
num toxins are under investigation is presented in Table 2.
The use of BoNTs has been extended to aesthetic applications for the reduction of facial lines. 
According to recent statistics, BoNT injections are now the most popular of all cosmetic pro-
cedures worldwide, both surgical and non-surgical [15], and, in the US, more than 6.6 million 
injections were performed in 2014 alone for aesthetic reasons [16]. There are currently three 
BoNT products approved by the FDA for use in glabellar lines (wrinkles that appear between 
Achalasia Dysphonia Neuromyotonia Rhinorrhoea and/or rhinitis
Alopecia Endometriosis Nystagmus Sialorrhea
Anal fissure Esophageal spasm Obesity Spasmodic dysphonia
Anismus Exotropia, esotropia, 
entropion
Orbital atrophy Stiff person syndrome
Atrial flutter Eyelid-opening apraxia Oscillopsia Stuttering
Autonomic dysreflexia Facial flushing Osteoarthritis Synkinesis
Benign prostatic 
hyperplasia
Fecal incontinence Some forms of pain Temporomandibular joint 
syndrome
Bruxism Frey’s syndrome Palatal myoclonus Tennis elbow
Carpal tunnel syndrome Gastroparesis Paratonia Tension headache
Cleft lip repair Gustatory sweating Peyronie’s syndrome Tetanus
Club foot Hemifacial spasm Piriformis syndrome Tremor
Constipation Hyperlacrimation Plantar fasciitis Trigeminal neuralgia
Cystitis Lateral epicondylalgia Protective ptosis Vaginismus
Depression Myofascial pain Psoriasis Ventricular arrhythmias
Diabetic polyneuropathy Myokymia Restless leg syndrome Vocal tics
Table 2. Not approved new indications for which botulinum toxins are under investigation [9, 13, 14].
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the eyebrows): abobotulinumtoxinA (Dysport®, Ipsen as the marketing authorisation holder 
with Galderma as distributor in the aesthetic indication), incobotulinumtoxinA (Xeomin®/
Bocouture®, Merz) and onabotulinumtoxinA (Botox®/Vistabel®, Allergan) (see Table 1). The 
facial aesthetic uses of BoNTs are extensive, mainly not approved and under investigation, 
and patient satisfaction with treatment is very high, with significant improvement in patient-
reported outcomes. Rhytides (skin wrinkles) regions for treatment include forehead, brow, 
region between the eyebrows, around the eyes (crow’s feet) and nose (bunny lines), smile 
(gummy smile), upper lip, corners of the mouth, jaw, chin and neck area [16, 17].
Despite intense use of BoNTs in clinical practice, approval and labelling guidance does not 
exist to address key questions such as where BoNTs fit amongst various treatment options 
for a given condition, recommendations of one product over another for a given indication or 
clinical differences in potency and duration of action (see Refs. [8, 18]).
3. Disease and bioterrorism threat
Botulism is a rare but potentially fatal disease caused by BoNT intoxication. Botulism is char-
acterised by a descending flaccid paralysis with symptoms of cranial nerve dysfunction such 
as diplopia (double vision), dysphagia (difficulty in swallowing), pupillary dilation and pto-
sis (drooping eyelids), progressing to respiratory failure and, in rare occasions if not provided 
with suitable intensive care and life support, ultimately death. Fever and altered mental status 
are absent. The diagnosis of botulism is largely clinical and is confirmed by laboratory tests, 
sometimes including the detection of BoNTs in contaminated materials, food or bodily waste 
[19]. Botulism in humans is classified according to the route of entry of the toxin: food-borne 
botulism occurs after the ingestion of BoNT-contaminated food that contains the preformed 
toxin; infant botulism is the result of bacteria colonising the immature gastrointestinal tract of 
infants which then produce and release the toxin in situ; wound botulism results from spore 
contamination into the tissue and is mostly associated with injection drug abuse; and iatro-
genic botulism can occur as a result of excessive BoNT use either for therapeutic or cosmetic 
use [20]. Inhalation botulism is also a possibility, if the toxin were to enter through the respira-
tory tract. However, inhalation botulism is rare and does not occur naturally [21].
A stable number of cases of botulism have been reported in Europe (i.e. European Economic 
Area, comprised of 31 countries) in recent years. During the period 2007–2014, an average of 
115 cases per year of confirmed botulism occurred, and 5% of those were fatal [22]. A very 
similar numbers in the US were reported by the Centres for Disease Control and Prevention 
(CDC) for the same period (2007–2014), with an average of 143 confirmed cases per year, with 
2% of those being fatal. According to the CDC, the most numerous cases were of infant botu-
lism, but wound and food-borne botulisms were also presented yearly, plus a minor percent-
age of cases of unknown aetiology [23].
There is currently no approved pharmacological treatment for BoNT intoxication in humans, 
and recent efforts have focussed on the development of (1) vaccines from partially purified tox-
ins, (2) use of specific antitoxin antibodies and (3) small molecule inhibitors [20, 24]. Once an 
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outbreak occurs, medical treatment includes treatment with the botulin heptavalent antitoxin 
and consideration of admission to an intensive care unit with mechanical ventilation until recov-
ery. Botulism is not contagious, and standard precautions are sufficient for infection control [19].
Botulism also occurs in animals and begins with the growth of the BoNT-producing bacteria in 
decaying carcasses followed by the release of the toxin into the environment. Both toxin and bac-
teria can spread via transmission of BoNT-insensitive animals such as maggots and other inverte-
brates that are consumed by healthy BoNT-sensitive animals, which eventually die and allow the 
growth of the bacteria and the subsequent production of the toxin to self-amplify the cycle [20].
Partly due to the fact that no effective treatment is available for BoNT intoxication in humans 
and the perceived ease in which it could be used in a bioterror attack, BoNT is classified as a 
potential bioterrorism weapon by the US CDC. BoNT belongs to the category A, the highest 
level of concern regarding public health and need of preparedness. Only five other agents 
are classified as category A agents, those being anthrax (Bacillus anthracis), bubonic plague 
(Yersinia pestis), smallpox (Variola major), tularemia (Francisella tularensis) and arenaviruses 
causing viral hemorrhagic fevers [19]. A contentious paper from 2005 regarding ease of BoNT 
intoxication through cow’s milk destined for human consumption calculated if would take 
only 4 g of BoNT, e.g. roughly equivalent to 1 teaspoon of granulated sugar, to poison over 
400,000 people [25]. The publication of that research opened a public safety debate within the 
scientific community regarding BoNT dual-use research [26], which was reopened when the 
allegedly new BoNT/H type was originally reported [27]. However, it should be noted that 
BoNTs are much more toxic (in the range of 100–1000 times) when injected than when admin-
istered orally; and delivery by aerosols is considered inefficient [20].
4. Historical overview of BoNT discovery
BoNT/A is the most potent toxin known to man, with a reported estimated human lethal 
dose of 1.3–2.1 ng/kg intravenously or intramuscularly and 10–13 ng/kg when inhaled [4]. 
Not surprisingly, its effects have been known throughout history long before the molecular 
identity of the toxin was elucidated. Botulism-like symptoms were known by ancient Greeks 
and Egyptians, and the Byzantine emperor Leo IV (886–911 AD) banned ‘blood sausage’ as it 
caused a fatal illness. It was not until around a thousand years later that following a number 
of sausage poisoning outbreaks in Germany the first accurate and complete description of the 
symptoms of food-borne botulism was described between 1817 and 1822 by J. Kerner. The 
extracted causative agent was named ‘sausage poison’ and was believed to be a ‘fatty acid’. 
Later, a German physician named Muller referred to the sausage poisoning as botulism from 
the Latin name for sausage, ‘botulus’ [4, 28].
The first isolation of the bacteria responsible for producing the toxic agent causing botulism 
was performed by the Belgian professor Emile Pierre van Ermengem and was termed Bacillus 
botulinus. Its name was changed to Clostridium botulinum when the aerobic Bacillus genus was 
separated from the anaerobic Clostridium genus [29]. To date, six different BoNT-producing 
bacterial groups are known; all have been taxonomically classified as clostridia. These  clostridia 
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produce seven different serotypes of botulinum toxin, termed BoNT/A to BoNT/G. BoNT/A, 
BoNT/B and BoNT/F were discovered following incidences of food-borne botulism, reminis-
cent of the original ‘sausage poisoning’, whereas BoNT/C, BoNT/D and BoNT/E were discov-
ered following incidences of botulism in animals [27] (see Figure 1). BoNT/G, discovered in 
1970, was reported in a sample extracted from soil, and to date there has not been reported 
cases of botulism caused by BoNT/G in the wild affecting either humans or animals [30]. A 
possible eighth type, initially termed BoNT/H was reported in 2013, but later reclassified as a 
BoNT/FA hybrid [31].
Despite Kerner suggesting the potential of BoNT as a therapeutic agent in conditions of mus-
cular hypercontraction and glandular hypersecretion, it was not until around 150 years later 
Figure 1. Timeline of the discovery of the seven botulinum toxin types. For context, also depicted are the dates of the first 
accurate description of botulism and the first use of botulinum toxins as therapeutic agent. A proposed eighth type was 
initially reported in 2013, now classified as an F/A hybrid toxin. For details see Refs. [2, 27, 28].
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that the first clinical application was made. In 1981, Dr. Alan B. Scott at what was formerly 
known as the Smith-Kettlewell Institute of Visual Science, San Francisco, California, USA, 
used BoNT/A for the treatment of strabismus as an alternative to surgical intervention. The 
original name of the drug was Oculinum®, and its rights were later acquired by Allergan Inc., 
which changed the name of the drug to Botox®.
5. The producing bacteria: types of toxin and nontoxin proteins
Upon the first description of the botulism symptoms (see above), the initial hypothesis was 
that botulism was caused by a toxin produced by a single bacterial organism, as is the case 
for the closely related toxin tetanus toxin and its producing bacteria Clostridium tetani [32]. 
However, it soon became apparent that different types of toxin and different producing bac-
teria existed for BoNT [29].
In 1910–1919, serological methods were introduced for categorisation of the toxin-producing 
bacteria and for the toxins themselves, that are still in use today [33]. Biochemical and molecu-
lar techniques have complemented those initial classifications and have confirmed the pres-
ence of multiple species of BoNT-producing clostridia and multiple species of BoNT proteins. 
BoNT-producing bacteria are Gram-positive, anaerobic, spore-forming and rod-shaped organ-
isms and are commonly found in any soil or water environment. The seven distinct serotypes 
differ by 37–70% in amino acid sequence [34]. Early observations pointed to a level of intratypic 
serological diversity that led to variants within serotypes to be called sub(sero)types and a pro-
posal that new subtypes would differ by 2.6% at the protein sequence level. However, this rule 
is not consistently applied today throughout all the subtypes [35]. It is considered that 41 indi-
vidual toxins exist and the various toxin subtypes are given a letter designation for the toxin 
serotype followed by a sequential number in order of discovery, e.g. BoNT/A1 and BoNT/E11. 
Only 4 serotypes currently present subserotypes, namely BoNT/A (8 subtypes), BoNT/B (8 sub-
types), BoNT/E (12 subtypes) and BoNT/F (7 subtypes) (see Figure 2). Interestingly, BoNT/C 
and BoNT/D occur naturally as well as hybrid toxins, termed BoNT/CD and BoNT/DC. A third 
naturally occurring hybrid, BoNT/FA, was initially proposed as the new serotype BoNT/H fol-
lowing its discovery in 2013 but later reclassified as a hybrid toxin [36].
Current classification of BoNT-producing clostridia is according to group designation based 
on metabolic biochemical criteria (see Table 3). The metabolic groups represent distinct spe-
cies of Clostridium botulinum (Groups I to III) and Clostridium argentinense (Group IV), and these 
species include non-toxigenic as well as neurotoxigenic members. In addition, Clostridium 
baratii and Clostridium butyricum are also known to produce BoNTs (Groups V and VI). To 
add to the confusion, some Clostridium botulinum strains do not produce BoNT, in particu-
lar if subcultured repeatedly in the laboratory; and some additional toxins are produced by 
the neurotoxigenic Clostridium botulinum, such as C2 toxin, C3 exoenzyme and botulinolysin. 
However, no alternative nomenclature for this group of organisms has been accepted [32].
Clostridial strains in different groups can produce the same toxin (e.g. Groups I, II and V pro-
duce BoNT/F), and bivalent toxin combinations within the same strain have been identified. 
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When more than one toxin is produced by a single strain, such as Ba or Bf, the capital letter desig-
nates the toxin produced in greater amounts. If a gene is present but not expressed, it is denoted 
between brackets, for example, A(B); and if a gene is present but truncated, it will have an apos-
trophe to indicate this fact, such as A(B′). This diversity in BoNT-producing bacterial strains 
is the result of toxin gene associations with transposases such as insertion sequence elements, 
recombinases, the acquisition of plasmids or infection by phage [37], within and between the 
Figure 2. Phylogenetic tree depicting the relationship of the 41 known botulinum neurotoxins. Individual FASTA files 
were accessed through the NCBI portal (NIH, USA), and the protein alignment and phylogram were constructed using 
the online software Clustal Omega (EMBL-EBI, Germany).
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groups and species. Groups IV–VI have the toxin genes located in the chromosome, considered 
less mobile, whereas Group III has the toxin genes in highly mobile elements such as plasmids 
and bacteriophages. Groups I and II have a mixture of chromosome and plasmid localisation 
[38]. A recent genetic study of C. botulinum strains causing human botulism in France showed 
that the genetic diversity of the BoNT-producing organism appeared as a result of multiple and 
independent genetic rearrangements and not from a single evolutionary lineage [39].
All seven BoNT serotype toxins are released from the producing bacteria as large protein 
complexes with a number of neurotoxin-associated proteins (NAPs) to become highly potent 
oral toxins, often ingested in contaminated foods [38, 40]. The NAPs are encoded together 
with the bont gene in one of two different gene clusters, the hemagglutinin (HA) cluster or 
the orfX cluster. Both clusters encode the nontoxic non-hemagglutinin (NTNHA) protein, 
which assembles with BoNT to form the smaller of the progenitor toxin complexes. BoNT/A, 
BoNT/B, BoNT/C and BoNT/D complexes contain HA, whereas BoNT/E and BoNT/F com-
plexes do not contain HA. The components of the BoNT complex vary with neurotoxin sero-
types and the Clostridium strain producing them. BoNTs are produced in three progenitor 
forms: M (medium), L (large) and LL (extralarge) complex. The M form consists of the neuro-
toxin (of 150 KDa) with NTNHA and has a total weight of ~ 300 KDa. The L and LL complexes 
consist of several HA proteins besides the BoNT and NTNHA, and its molecular weight is ~ 
500 KDa for the L form and ~ 900 KDa for the LL form. The function of the proteins encoded 
in the orfX genes remains unknown [41]. NAPs are known to protect BoNTs against the pro-
teases of the gastrointestinal tract and the acidic conditions of the stomach and to facilitate the 
intestinal trans-epithelial delivery to the toxin into the lymphoid and general circulation [38]. 
The role of NAPs in the producing bacteria is not known. Recently, it has been proposed that 
the primary role of NAPs and in particular that of NTNHA is to protect BoNTs from damage 
in the decaying biological material where the toxin is mostly produced in the wild [20].
Clostridial bacteria Group BoNT 
serotype(s) 
produced
Mixture of serotype(s) 
produced by a single 
strain
Nontoxinogenic bacteria 
belonging to the same group
Clostridium botulinum I A, B, F A(B), A(B′), Ab, Af, Ba, 
Bf, Bf/a
Clostridium sporogenes
Clostridium botulinum II B, E, F – Clostridium taeniosporum
Clostridium botulinum III C, D,
CD hybrids
DC hybrids
– Clostridium novyi
Clostridium 
argentinense
IV G – Clostridium argentinense
Clostridium subterminale
Clostridium hastiforme
Clostridium baratii V F – Clostridium baratii
Clostridium butyricum VI E – Clostridium butyricum
Table 3. BoNT-producing clostridial species, see Refs. [20, 29, 38].
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Until recently, BoNTs were believed to be produced exclusively by clostridia organisms. In 
2015, the first homologue of BoNTs was described within the genome of the rice fermenta-
tion bacteria Weissella oryzae SG25 [42]. Bioinformatic analysis of the genomic sequences of 
W. oryzae SG25 revealed one gene with a very similar structure to BoNTs, whereas a second 
gene showed partial similarity with the BoNT-associated NTNH proteins [42]. Recombinant 
expression of the BoNT-like protein revealed that it shares similarities with BoNT/B regarding 
its targeting profile and it is also expected to block neurotransmitter release. The new BoNT-
like protein showed no serological cross-reactivity with the seven known BoNT serotypes, 
and it was dubbed BoNT/Wo by the authors [43].
6. Structure-function of BoNT toxins
BoNTs are zinc metalloproteases consisting of three major domains. Produced as a single poly-
peptide of 150 KDa, BoNTs require activation by cleavage of the polypeptide post-translationally 
resulting in the so termed heavy chain, of ~ 100 KDa, and a light chain (LC), of ~ 50 KDa, held 
together by a disulphide bridge between the two chains [44]. Functionally, the light chain hosts 
the metalloprotease domain, and the heavy chain comprises both the binding domain (H
C
) and 
the translocation domain (HN). The producing bacteria in Groups I, III and IV (see Table 3) are 
proteolytic strains and will release the cleaved active product, whereas the products of the other 
producing bacteria are believed to be activated by proteases of the intoxicated organism [38].
The neuromuscular junction is the natural target of BoNTs, and intoxication follows an intri-
cate multistep mechanism [20, 45], in which the toxin-associated proteins of the progenitor 
toxin complex play a crucial role. For an overview of the routes of entry and mechanism of 
action of the toxin, see Figure 3.
Unintentional BoNT entry into the organism occurs mainly through ingestion of contaminated 
foods leading to food-borne botulism (see above) or through wounds [20]. Alternatively, and in 
particular in cases of infant botulism, the producing bacteria can colonise the immature gastro-
intestinal tract and produce the exotoxin in situ. The progenitor complex allows BoNTs to effec-
tively cross the intestinal trans-epithelial barrier and reach the lymphoid and general blood 
circulation. Under neutral and alkaline environments, such as in the bloodstream, the complex 
dissociates and the naked toxin is able to target neuromuscular junctions [46]. In clinical appli-
cations, the toxin is delivered locally to the site of action. BoNT entering the body undergoes a 
relatively short distribution phase which sees the toxin selectively targeting peripheral nerve 
endings, and an elimination phase that comprises both (1) an interneuronal metabolism fol-
lowing cellular entry and (2) systemic metabolism and elimination which are assumed to be 
through the liver [47].
Upon reaching the neuromuscular junction, BoNTs are able to specifically target nerve terminals 
using their Hc-binding domain and internalise through endocytosis. Once in the acidic envi-
ronment of the endosome, the BoNT HN domain translocates the LC domain into the cytosol, 
allowing the Zn+2 metalloprotease enzyme to cleave target soluble N-ethylmaleimide-sensitive 
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factor attachment protein receptor (SNARE) proteins. SNARE proteins constitute an essential 
part of the machinery for neurotransmitter release in eukaryotic cells, and once their function is 
compromised by BoNTs, release of acetylcholine in the neuromuscular junction is prevented [19].
Although all serotypes, and even the most recently described BoNT-like protein BoNT/Wo 
[43], share a multidomain structure, crystallographic data has revealed that the molecular 
arrangement in the 3D space varies. BoNT/A and BoNT/B present an ‘open butterfly’ struc-
ture, whereas BoNT/E has a ‘closed butterfly’ organisation when viewed taking the HN trans-
location domain as a sagittal axis [48, 49]. In Figure 4, three different representations illustrate 
the organisation of BoNT/A and BoNT/E. This differential 3D topology has been credited to 
confer particular characteristics to BoNT serotypes, such as a faster way of entry for BoNT/E 
compared to BoNT/A [50].
6.1. Binding domain
BoNTs belong to the family of AB exotoxins, consisting of an ‘A’ toxic domain and a ‘B’ 
binding domain. AB toxins such as cholera toxin, lethal factor from Escherichia coli and Shiga 
toxin use gangliosides as their cellular receptors; whereas anthrax toxin and ricin have pro-
tein receptors identified as their targets [51].
Figure 3. Mode of action of botulinum toxins; for details in each step, see Refs. [20, 45].
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In the case of BoNTs, a dual receptor theory was postulated [52]. This dual-binding anchorage is 
credited for the high affinity and specificity by which BoNTs target neurons. All serotypes share 
a similar binding site for the interaction with the oligosaccharide portion of a polysialoganglio-
side. For BoNT/A, BoNT/B, BoNT/E, BoNT/F and BoNT/G, the conserved ganglioside-binding 
site SXWY has been reported, whereas BoNT/C, BoNT/D and BoNT/DC have analogous sites for 
ganglioside binding at a similar position [53]. A second, non-conserved binding site that binds a 
protein receptor has been identified in several BoNTs [54]. BoNT/A, BoNT/E and BoNT/F bind 
the family of synaptic vesicle protein SV2, whereas BoNT/B, BoNT/D and BoNT/G recognise a 
short peptide sequence in the luminal domain of the family of synaptic vesicle protein synapto-
tagmin. A protein receptor has not yet been identified for BoNT/C, which uses a dual ganglio-
side mechanism [55]. A second protein receptor has been identified for BoNT/A, namely, FGFR3 
[56]. Crystal structures of the H
C
 domains in complex with their receptors, where available, have 
contributed a major advance in the understanding of BoNT-cell interactions.
Recently, glycan motifs in both gangliosides [53] and protein receptors [57, 58] have emerged 
as key players in the targeting of BoNTs to the neuronal membranes, albeit glycosylation is 
not required for binding for all BoNTs [38].
Figure 4. Structural and functional domains of (A) BoNT/A (PDB 3BTA) and (B) BoNT/E (PDB 3FFZ). Hc = binding 
domain, HN = translocation domain, LC = light chain protease domain. Upper panels: ribbon diagram of the respective 
crystal structures. Middle panels: diagram depicting the three-dimensional organisation of the domains within 
the structure. Lower panels: simplified two-dimensional block diagram in which the HN and LC can be seen being 
connected by a conserved disulphide bridge. Structural image created from crystallographic using the MOE software 
(Molecular Operating Environment 2013.08; Chemical Computing Group Inc., Montreal, Canada).
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6.2. Translocation domain
Neuronal internalisation triggers the translocation of the LC domain to the cytosol, separating 
it from the HN and H
C
 domains and thus allowing it to cleave the cytosolic target SNARE pro-
teins. In neurons in vitro, internalisation of BoNT/A and translocation of the LC into the cytosol 
occur rapidly, with estimates either side of ~ 60 minutes [59]. Following entry into the synaptic 
vesicle, the proton pumping action of the v-ATPase present on the synaptic vesicle membrane, 
responsible for the loading of neurotransmitters into the vesicle, will acidify the organelle and 
produce the necessary environment for the LC to translocate. Treatments that inhibit internali-
sation, synaptic vesicle recycling, or acidification also inhibit BoNT action [60].
Of the various steps of the cellular mechanism of intoxication, membrane translocation for 
the LC is least understood at the molecular level, and several models have been suggested 
[48]. The first model proposes that upon acidification of the lumen of the synaptic vesicle, 
HN penetrates the membrane and forms an ion channel assisting a partially unfolded LC 
to pass through it. This model has been revised and a new proposed mechanism includes 
binding of the toxin domains to the luminal membrane of the synaptic vesicle, and following 
acidification both HN and a partly unfolded LC will destabilise and penetrate the membrane. 
LC will move to the cytosolic side, refold and be released upon reduction of the disulphide 
bond. At the same time, segments of the HN insert in the membrane and assemble an ion 
channel. The main difference between these models is that in the first model, channel forma-
tion by HN is an early event and translocates LC, whereas in the second model, the channel 
formed by HN occurs as a consequence of the LC translocation. In both models, the reduction 
of the disulphide bond is essential to free the LC at the end of the translocation step, and the 
enzyme thioredoxin and its regenerating enzyme thioredoxin reductase have been identified 
as the cellular system responsible for the reduction of the disulphide bridge [61]. Following 
translocation, another key protein recently identified is Hsp 90, which may act as a chaperone 
assisting the refolding of the LC once in the cytosol [62].
Different models have been proposed for the mechanism by which BoNT domains approach 
the membrane, which may have physiological consequences. BoNT/E is thought to owe its 
rapid translocation to its ‘closed butterfly’ three-dimensional structure in which the Hc and 
LC are in close proximity [50], whereas BoNT/A and BoNT/B, which in principle share the 
‘open butterfly’ configuration, would approach the membrane differently [63].
6.3. Protease domain
The LC domain is a metalloprotease that cleaves SNARE proteins within the nerve terminal 
cytosol, resulting in the inhibition of the acetylcholine release which causes a reversible neu-
roparalysis [44].
SNARE proteins are membrane-associated proteins and comprise a large family of proteins 
that are responsible for the binding and fusion of vesicles to membranes. In humans, there 
are 38 different types of SNARE proteins [64]. SNARE proteins that mediate the exocytosis of 
neurotransmitter vesicles with the plasma membrane of neurons are the target substrates of 
BoNTs [65]. In addition to inhibiting neurotransmitter release, SNARE cleavage by BoNT also 
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affects trafficking of proteins, for example, TRPV1 and TRPA1 receptors to the neuronal sur-
face [66]. BoNT/A, BoNT/C and BoNT/E target SNAP-25, whereas BoNT/B, BoNT/D, BoNT/F 
and BoNT/G target VAMP1, VAMP2 and VAMP3 proteins. BoNT/C is unique amongst BoNTs 
in targeting two different SNARE types, as it targets syntaxin 1 and syntaxin 2 besides also 
targeting SNAP-25. Hydrolysis of the SNARE proteins occurs at a unique cleavage site spe-
cific to each BoNT [35].
No additional target substrates have been reported for BoNTs beyond SNARE proteins. This 
may be due to the extensive interaction that BoNTs make with the target proteins, including 
the cleavage site, which may be responsible for the exclusive specificities to SNARE isoforms 
in a species-specific manner [48].
The length of BoNT-induced intoxication may depend on (1) how long the cleaved SNARE 
proteins remain in the cytosol and the ability of the cleaved SNARE proteins to maintain 
the block to exocytosis, (2) how long the BoNT protease remains in place to cleave newly 
synthesised SNARE proteins, (3) the rate at which the neuron is able to replenish uncleaved 
SNARE proteins relative to ongoing cleavage, and (4) the ability of the presynaptic terminal 
to remodel in order to overcome the temporary paralysis. There is preclinical evidence for all 
these hypotheses [67]. The ubiquitination pathway has been proposed as a main mechanism 
responsible for degradation of the LC in the cytosol, thus terminating BoNT activity [68].
6.4. Three domains and four functions
Despite intense activity in recent years towards understanding the basic mechanism of action 
(MOA) of BoNTs, currently known structure-activity relationships of the four BoNT func-
tions (binding, internalisation, translocation and SNARE cleavage at the nerve terminals of 
the neuromuscular junction) within three domains (Hc, HN, and LC) are not fully under-
stood. Current gaps in basic understanding include molecular details of the specificity of the 
binding of each BoNT to neurons, entry into the nerve terminal and translocation of the LC, 
the correlation between SNARE cleavage and neuroparalysis and the length of BoNT-induced 
neuroparalysis. For example, it is known that the length of paralysis varies with BoNT type, 
dose, animal species and type of nerve terminal (from 3 to 4 months for skeletal nerve termi-
nals to 12–15 months for autonomic cholinergic nerve terminals) [54, 69]. Furthermore, there 
are emerging functions that do not fall within the canonical intoxication pathway.
Regarding discrete functions of BoNT domains, there is increasing evidence that, in addition 
to their individual functions, each domain influences the other to work in concert to achieve 
BoNT intoxication. For example, the binding domain is not necessary for cell entry or LC 
translocation, but it determines the pH threshold for HN channel formation during the trans-
location step [70].
Entry of BoNTs has also been reported independent of synaptic vesicle recycling [71]; and 
retrograde transport within non-acidifying organelles, a characteristic of the related teta-
nus toxin, has been described for BoNT/A and BoNT/E [72]. Effects of BoNT in the central 
nervous system, such as in pain states, have also been reported, indicating actions beyond 
the neuromuscular junction that would involve retrograde transport of the toxin [73].
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Furthermore, BoNTs, and in particular BoNT/A, are known to exert further actions unrelated 
to the cleavage of SNAP-25, at doses/concentrations that prevent SNAP-25-mediated neu-
rotransmitter release. These activities include (1) increasing the proteosomal degradation of 
the protein RhoB in arachidonic-mediated neuroexocytosis, (2) induction of neuritogenesis, (3) 
reduction of cellular proliferation and (4) effects on gene expression, both in in vivo and in vitro 
settings [74]. The significance of these findings is not yet fully understood, but opens exciting 
opportunities to expand the use of BoNTs beyond their classical SNARE-cleaving MOA.
7. New therapeutics
7.1. Improvements on current products
The four FDA-approved formulations in the market for BoNT products are manufactured 
starting with the fermentation of the respective C. botulinum [1]. As a result, the manufac-
turing processes come with their own challenges, namely, (1) the anaerobic requirements 
mean that oxygen must be excluded from the first stages of the production system as the C. 
botulinum are obligate anaerobes, (2) the production of the toxin progresses from the first 
stages of growth, so health and safety measures are paramount throughout the manufac-
turing process, (3) sporulation of the bacteria can occur at low levels during the growth 
stages, but particularly when the bacterial life cycle ends and the bacteria die, and (4) the 
nutritional growth requirements of C. botulinum are not known in detail, which results in 
complex growth media adding extra degrees of complexity [75]. Recombinant production 
of BoNTs in non-obligate anaerobes and non-sporulating organisms, already widely used 
in the research setting (e.g. Ref. [76]), will simplify the manufacturing process enormously, 
as well as facilitate molecular engineering approaches that are state of the art in the protein 
field.
One aspect that is still contentious about the current BoNT drug products is the presence/
absence of the ancillary non-toxic associated proteins (NAPs). In particular, it is not clear what 
role these proteins, which are critical to protect the toxin during entry through the gastroin-
testinal tract, are playing when the toxin is injected, as is the case for the current therapeutic 
and aesthetic uses. AbobotulinumtoxinA (Dysport®) and onabotulinumtoxinA (Botox®) pres-
ent a complex of BoNT plus non-toxic associated proteins (NAPs), whereas incobotulinum-
toxinA (Xeomin®) does not have NAPs present in its formulation [11]. RimabotulinumtoxinB 
(Myobloc®) is also a neurotoxin complex in which the BoNT is associated with hemagglutinin 
and non-hemagglutinin proteins [1].
Regarding distant spread, the FDA prompted an inclusion of a black box warning for all FDA-
approved BoNT products, as follows: ‘The effect of all botulinum toxin products may spread 
from the area of injection to produce symptoms consistent with botulinum toxin effects. These 
symptoms have reported hours to weeks after injection. Swallowing and breathing difficul-
ties can be life-threatening and there have been reports of death’ [1]. Ancillary proteins are 
not likely to play a role in distant spread since studies show that there were no differences in 
product diffusion when the same dose was injected with the same technique [15].
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Triggering of immune responses by BoNT use, and possibly triggering non-responsiveness 
to treatment, is a controversial topic since, despite dissociation from the toxin NAPs, HA 
and NTNHA proteins form part of the protein load of the injection [77]. Following meta-
analysis of clinical incidence of neutralising antibody immunogenicity is often revealed as a 
very minor issue with low, single-digit percent occurrence with the current main products 
[78]. Differences have been seen with an older product (which exhibited higher incidence of 
neutralising antibodies), dosing frequency and cumulative dose [79].
New products, produced using different manufacturing processes and with different final 
formulations, may help address the above issues and indeed as well for the existing natu-
ral products, which have not changed formulation or manufacturing process significantly in 
the last 20 years [75]. Alternative new products include Nabota® (Daewoong Pharmaceutical 
Co., Korea), which consists of BoNT/A obtained following a special purification process, and 
RT002 (Revance Therapeutics Inc., USA), which is an injectable formulation of BoNT/A con-
taining a polycationic excipient developed to limit diffusion of the toxin into adjacent tissues 
and to be longer acting than the current BoNT products, amongst others [2, 9]. The use of 
hydrogels and liposomes, for example, in treatments for bladder or gastric disorders, has also 
been reported as novel BoNT formulations being investigated [80]. Liquid formulations for 
BoNT/A products, already in the market for BoNT/B, are actively being pursued, and their 
use would preclude the need of reconstitution of the products [75].
7.2. Molecular engineering of BoNTs
Given the natural diversity of BoNTs, with 7 serotypes and over 40 individual subtype proteins, 
it is surprising that the leading marketed products are restricted to only two serotypes, BoNT/A 
and BoNT/B. So far, anecdotal use of BoNT/C and BoNT/F was reported few years ago [81]. 
The current landscape of new therapeutics include, for example, the potential use of the short-
acting BoNT/E1 as reported in WO2014068317 [82], the use of a BoNT/B toxin with increased 
binding affinity for its human cognate receptor synaptotagmin II as reported in WO2013180799 
[83] as well as BoNT/A3 (WO2013049139 [84]). In particular, serotype BoNT/A2 has been exten-
sively studied in Japan as an alternative BoNT/A with differentiated biology [85, 86].
Molecular engineering approaches facilitate the harnessing of inherent characteristics present 
in the already diverse natural BoNTs [87] but also allowing the introduction of new proper-
ties. When considering engineering approaches, all three BoNT domains offer exciting oppor-
tunities; for a recent review, see Ref. [5]. Firstly, engineering of the Hc domain could facilitate 
(1) alternative receptor targets to modify specificity, (2) allow immune epitope modification 
and (3) add/modify receptor-binding motifs and related structural regions to modify affinity. 
Secondly, engineering the HN domain could modulate cargo capacity and pH dependency 
of translocation of cargo. Finally, LC engineering could provide (1) substrate specificity, (2) 
desired intracellular localisation, (3) modification of immune epitopes and (4) modification/
manipulation of self-proteolysis and degradative pathways.
An example of such engineering approaches is targeted secretion inhibitors (TSI), in which 
the Hc domain of BoNT is substituted by an alternative cellular targeting domain (e.g. see 
WO2006059093 [88]), which will be discussed in the next section.
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7.3. Example of new therapeutics: targeted secretion inhibitors
Natural BoNT toxins target neuronal terminals, and their duration of action is often measured 
in months. These characteristics have made them very successful therapeutic and aesthetic 
agents (see Section 1 above), but it also limits their use to their specific target cells. Given that 
SNARE proteins underpin a universal mechanism of secretion in eukaryotic cells, an engi-
neering approach that would lead to cleaved SNARE proteins in a wide range of (hypersecret-
ing) cells would provide novel and exciting therapeutic opportunities. In TSI, the Hc-binding 
domain of BoNTs is substituted by an alternative cell-binding moiety, and the resulting pro-
teins are not neurotoxins but a new class of biopharmaceuticals [89].
The basis for the TSI platform development is a functional fragment from BoNTs comprising 
the LC and HN domain, termed LHN. LHN proteins are proteolytically cleaved during activa-
tion, and the two domains remain connected by a disulphide bridge, as is the case in the paren-
tal BoNTs. LHN/A, LHN/B, LHN/C and LHN/D are amenable to recombinant expression in 
E. coli and have all been described as functionally active, resembling the respective parental 
toxin [90, 91]. Examples of TSI include those where the targeting domain is comprised of wheat 
germ agglutinin, nerve growth factor, an epidermal growth factor receptor (EGFR) targeting 
ligand or a growth hormone-releasing hormone receptor (GHRHR) targeting ligand. These 
TSI have shown that it is possible to achieve internalisation of the active BoNT LC contained 
in their structure into non-neuronal cells otherwise resistant to the parental BoNT [92–94].
The structures of LHN/D and a GHRHR-targeted TSI/D, SXN101959, are shown in Figure 5. 
When compared with BoNT structures depicted in Figure 3, it is seen that the BoNT Hc 
domain is absent in the LHN structure and, in the case of the TSI a new targeting moiety 
takes the place of Hc. Often, the new targeting moiety is considerably smaller than the 
original Hc domain of the parental BoNT. That poses its own challenges regarding ligand 
accessibility, and so linkers and spacers are frequently used. Furthermore, in the case of this 
GHRHR ligand, a free N-terminus of the peptide is required for optimal activation of the 
GHRHR receptor [95], which has prompted the position of the ligand to be at the N-terminal 
end of HN when compared to the Hc (located at the C-terminal of HN in the natural struc-
ture). Functionally, this TSI has been shown to exert a powerful and reversible inhibitory 
action on the endocrine growth hormone and insulin-like growth factor-I axis [96].
Little is known about TSI intracellular trafficking, and it is generally assumed that the BoNT 
four-step MOA (binding, internalisation, translocation and SNARE cleavage) will apply. A 
study using a GHRHR-targeted TSI/D reported an intracellular, punctate, immune-staining 
pattern indicative of the presence of the TSI in endosomes [97]. In a recent paper, internalisa-
tion of an EGFR-targeted TSI/A and BoNT/A was assessed in the same cellular system [98]. The 
EGFR-targeted TSI/A partially internalised in an intracellular compartment consistent with 
endosomes, whereas BoNT/A did so in a different compartment consistent with synaptic vesicle 
recycling. Both proteins were able to cleave the cytosolic SNARE protein target SNAP-25. 
The study confirmed that BoNT domains are a versatile tool to extend the pharmacological 
effect of BoNTs beyond the natural target of the neuromuscular junction.
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In addition to the delivery of SNARE cleaving activity into non-neuronal cells, TSI can also 
be used to provide alternative targeting to neurons with improved neuronal selectivity. 
One such example is neuronal targeting via the nociceptin receptor, which reached Phase II 
clinical trials for post-herpetic neuralgia and overactive bladder (WO2006059093) [88, 99].
8. Conclusions
BoNTs are key therapeutic agents with a seemingly ever-increasing list of new applications. 
The fascinating modular molecular architecture and natural diversity of BoNTs is the base for 
future therapeutics, being developed using recombinant technologies, new formulations and 
engineered new pharmacological properties.
Figure 5. Structural and functional domains of LHN/D and a GHRHR-targeted TSI/D. (A) Crystallographic data of 
LHN/D (PDB 5BQN). (B) Crystallographic data for the GHRH-targeted TSI/D (PDB 5BQM) in which the targeting 
domain has been added using molecular modelling for illustration purposes. The ribbon to the right of the LC and 
HN domains corresponds to the GHRHR ligand plus the spacer, as illustrated in (C). (C) Simplified block diagrams 
of the structures presented in (A) and (B), respectively. The HN and LC domains in both structures can be seen being 
connected by a conserved disulphide bridge. Structural images created using the MOE software (Molecular Operating 
Environment 2013.08; Chemical Computing Group Inc., Montreal, Canada).
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